KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Long-Term Investments (2020 - 2025)

Historic Long-Term Investments for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $93.3 million.

  • AbCellera Biologics' Long-Term Investments rose 1096.17% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 1096.17%. This contributed to the annual value of $82.3 million for FY2024, which is 2480.97% up from last year.
  • Per AbCellera Biologics' latest filing, its Long-Term Investments stood at $93.3 million for Q3 2025, which was up 1096.17% from $90.4 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Long-Term Investments registered a high of $93.3 million during Q3 2025, and its lowest value of $32.2 million during Q1 2021.
  • For the 5-year period, AbCellera Biologics' Long-Term Investments averaged around $66.4 million, with its median value being $65.9 million (2023).
  • Per our database at Business Quant, AbCellera Biologics' Long-Term Investments skyrocketed by 16140.7% in 2021 and then plummeted by 1068.3% in 2023.
  • AbCellera Biologics' Long-Term Investments (Quarter) stood at $50.3 million in 2021, then surged by 44.14% to $72.5 million in 2022, then dropped by 9.08% to $65.9 million in 2023, then increased by 24.81% to $82.3 million in 2024, then increased by 13.37% to $93.3 million in 2025.
  • Its last three reported values are $93.3 million in Q3 2025, $90.4 million for Q2 2025, and $81.6 million during Q1 2025.